{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T14:25:12Z","timestamp":1794925512033,"version":"4.9.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background and Purpose<\/jats:title><jats:p>Anti-muscle-specific kinase (MuSK) positive myasthenia gravis (MG) is characterized by a high relapsing rate, thus, choosing the appropriate oral drug regimen is a challenge. This study aimed to evaluate the efficacy of oral immunosuppressants (IS) in preventing relapse in MuSK-MG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This prospective cohort observational study included patients with MuSK-MG at Peking Union Medical College Hospital between January 1, 2018, and November 15, 2021. The patients were divided into 2 groups: those with (IS+) or without (IS-) non-steroid immunosuppressive agents. The primary outcome was relapsed at follow-up, and the log-rank test was used to compare the proportion of maintenance-free relapse between the groups; hazard ratio (HR) was calculated using the Cox proportional hazards models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty-three of 59 patients with MuSK-MG were included in the cohort, 14 were in the IS+ group, and 39 were in the IS- group. Twenty-four cases in the cohort experienced relapse at least once; the relapse rate was 2\/14 (14.3%) in the IS+ group and 22\/39 (56.4%) in the IS- group. At the end of follow-up, the proportion of maintenance-free relapse was significantly different between the two groups (log-rank \u03c7<jats:sup>2<\/jats:sup> = 4.94, <jats:italic>P<\/jats:italic> = 0.02). Of all the potential confounders, only the use of IS was associated with a reduced risk of relapse. The HR for relapse among patients in the IS+ group was 0.21 (95%CI 0.05\u20130.58) and was 0.23 (95%CI 0.05\u20130.93) in a model adjusted for age, sex, relapse history, highest Myasthenia Gravis Foundation of America (MGFA), and accumulated time of steroid therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study provides evidence that oral non-steroid immunosuppressive agents may be beneficial in reducing relapse in patients with MuSK-MG.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.877895","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T11:42:17Z","timestamp":1655206937000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Efficacy of Non-steroid Immunosuppressive Agents in Anti-Muscle-Specific Kinase Positive Myasthenia Gravis Patients: A Prospective Study"],"prefix":"10.3389","volume":"13","author":[{"given":"Ying","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhou","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0092-8674(00)81251-9","article-title":"The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo","volume":"85","author":"DeChiara","year":"1996","journal-title":"Cell."},{"key":"B3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1749-6632.2012.06781.x","article-title":"Management challenges in muscle-specific tyrosine kinase myasthenia gravis. Annals of the New York Academy of Sciences","volume":"1274","author":"Evoli","year":"2012"},{"key":"B4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fnmol.2020.00159","article-title":"Myasthenia gravis with antibodies against muscle specific kinase: an update on clinical features, pathophysiology and treatment","volume":"13","author":"Cao","year":"2020","journal-title":"Front Mol Neurosci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3389\/fneur.2020.00660","article-title":"MuSK-associated myasthenia gravis: clinical features and management","volume":"11","author":"Rodolico","year":"2020","journal-title":"Front Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve."},{"key":"B8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1756285615571873","article-title":"The emerging role of tacrolimus in myasthenia gravis","volume":"8","author":"Cruz","year":"2015","journal-title":"Ther Adv Neurol Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/TCRM.S14015","article-title":"Current and emerging treatments for the management of myasthenia gravis","volume":"7","author":"Sathasivam","year":"2011","journal-title":"Ther Clin Risk Manag."},{"key":"B10","doi-asserted-by":"publisher","first-page":"594152","DOI":"10.3389\/fneur.2020.594152","article-title":"Favorable effects of tacrolimus monotherapy on myasthenia gravis patients","volume":"11","author":"Fan","year":"2020","journal-title":"Front Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756285617721092","article-title":"Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China","volume":"10","author":"Zhou","year":"2017","journal-title":"Ther Adv Neurol Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol."},{"key":"B14","first-page":"1","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review","volume":"10","author":"Vincenzo","year":"2020","journal-title":"J Neurol Neurosurgery Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1136\/jnnp.2004.052415","article-title":"The features of myasthenia gravis with autoantibodies to MuSK","volume":"76","author":"Lavrnic","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1749-6632.2012.06812.x","article-title":"The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice","volume":"1274","author":"Burns","year":"2012","journal-title":"Ann N Y Acad Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jns.2010.09.033","article-title":"Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis","volume":"300","author":"Minami","year":"2011","journal-title":"J Neurol Sci."},{"key":"B19","first-page":"59","article-title":"Muscle-specific kinase autoimmune myasthenia gravis: report of a pediatric case and literature review","volume":"300","author":"Ben Younes","year":"2011","journal-title":"Neuropediatrics."},{"key":"B20","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","year":"2008","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s12883-021-02439-7","article-title":"Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study","volume":"21","author":"Zhao","year":"2021","journal-title":"BMC Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3389\/fimmu.2020.00707","article-title":"Muscle-Specific Kinase Myasthenia Gravis","volume":"71","author":"Borges L","year":"2008","journal-title":"Front Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"B24","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia Gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/BOR.0000000000000647","article-title":"Diagnosis and treatment of myasthenia gravis","volume":"31","author":"Mantegazza","year":"2019","journal-title":"Curr Opin Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.877895\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T11:42:21Z","timestamp":1655206941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.877895\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":27,"alternative-id":["10.3389\/fneur.2022.877895"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.877895","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fneur.2022.877895.s001","asserted-by":"subject"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"article-number":"877895"}}